Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
This is an open-label, non-randomised trial with two phases. The first phase, the Safety Run-In Phase, is to determine the recommended dose for the second phase, the Expansion Phase. Binimetinib will be taken twice daily (orally) and encorafenib will be taken once daily (orally). Dose levels by patient body surface area for binimetinib and encorafenib tablets/capsules are specified in the protocol.